ROIV vs. BNTX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, and VTRS
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.
Roivant Sciences vs.
BioNTech (NASDAQ:BNTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.
In the previous week, BioNTech had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 22 mentions for BioNTech and 15 mentions for Roivant Sciences. BioNTech's average media sentiment score of 0.37 beat Roivant Sciences' score of 0.37 indicating that BioNTech is being referred to more favorably in the media.
BioNTech received 95 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.87% of users gave Roivant Sciences an outperform vote while only 47.04% of users gave BioNTech an outperform vote.
BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Roivant Sciences has lower revenue, but higher earnings than BioNTech. Roivant Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
15.5% of BioNTech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
BioNTech has a net margin of -15.16% compared to Roivant Sciences' net margin of -119.54%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.
BioNTech presently has a consensus price target of $138.25, indicating a potential upside of 29.34%. Roivant Sciences has a consensus price target of $17.50, indicating a potential upside of 53.91%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than BioNTech.
Summary
BioNTech beats Roivant Sciences on 11 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ROIV) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy ROIV Stock Free ROIV Stock Alerts